113 related articles for article (PubMed ID: 26548976)
1. Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models.
Ye H; Tanenbaum LM; Na YJ; Mantzavinou A; Fulci G; Del Carmen MG; Birrer MJ; Cima MJ
J Control Release; 2015 Dec; 220(Pt A):358-367. PubMed ID: 26548976
[TBL] [Abstract][Full Text] [Related]
2. An injectable depot system for sustained intraperitoneal chemotherapy of ovarian cancer results in favorable drug distribution at the whole body, peritoneal and intratumoral levels.
Zahedi P; Stewart J; De Souza R; Piquette-Miller M; Allen C
J Control Release; 2012 Mar; 158(3):379-85. PubMed ID: 22154933
[TBL] [Abstract][Full Text] [Related]
3. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
[TBL] [Abstract][Full Text] [Related]
4. CD44-targeted microparticles for delivery of cisplatin to peritoneal metastases.
Li SD; Howell SB
Mol Pharm; 2010 Feb; 7(1):280-90. PubMed ID: 19994852
[TBL] [Abstract][Full Text] [Related]
5. Ovarian cancer spheroid shrinkage following continuous exposure to cisplatin is a function of spheroid diameter.
Tanenbaum LM; Mantzavinou A; Subramanyam KS; Del Carmen MG; Cima MJ
Gynecol Oncol; 2017 Jul; 146(1):161-169. PubMed ID: 28499648
[TBL] [Abstract][Full Text] [Related]
6. A cisplatin slow-release hydrogel drug delivery system based on a formulation of the macrocycle cucurbit[7]uril, gelatin and polyvinyl alcohol.
Oun R; Plumb JA; Wheate NJ
J Inorg Biochem; 2014 May; 134():100-5. PubMed ID: 24595010
[TBL] [Abstract][Full Text] [Related]
7. Experimental and clinical evaluation of cisplatin-containing microspheres as intraperitoneal chemotherapy for ovarian cancer.
Sugiyama T; Kumagai S; Nishida T; Ushijima K; Matsuo T; Yakushiji M; Hyon SH; Ikada Y
Anticancer Res; 1998; 18(4B):2837-42. PubMed ID: 9713471
[TBL] [Abstract][Full Text] [Related]
8. The influence of phospholipid on the physicochemical properties and anti-tumor efficacy of liposomes encapsulating cisplatin in mice bearing C26 colon carcinoma.
Alavizadeh SH; Badiee A; Golmohammadzadeh S; Jaafari MR
Int J Pharm; 2014 Oct; 473(1-2):326-33. PubMed ID: 25051111
[TBL] [Abstract][Full Text] [Related]
9. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
10. Folic acid tagged nanoceria as a novel therapeutic agent in ovarian cancer.
Hijaz M; Das S; Mert I; Gupta A; Al-Wahab Z; Tebbe C; Dar S; Chhina J; Giri S; Munkarah A; Seal S; Rattan R
BMC Cancer; 2016 Mar; 16():220. PubMed ID: 26979107
[TBL] [Abstract][Full Text] [Related]
11. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model.
Mabuchi S; Terai Y; Morishige K; Tanabe-Kimura A; Sasaki H; Kanemura M; Tsunetoh S; Tanaka Y; Sakata M; Burger RA; Kimura T; Ohmichi M
Clin Cancer Res; 2008 Dec; 14(23):7781-9. PubMed ID: 19047105
[TBL] [Abstract][Full Text] [Related]
12. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.
McKeage MJ; Kelland LR; Boxall FE; Valenti MR; Jones M; Goddard PM; Gwynne J; Harrap KR
Cancer Res; 1994 Aug; 54(15):4118-22. PubMed ID: 8033145
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of heparin-polyethyleneimine nanogels delivering claudin-3-targeted short hairpin RNA combined with low-dose cisplatin on ovarian cancer.
Liu L; Gou M; Yi T; Bai Y; Wei Y; Zhao X
Oncol Rep; 2014 Apr; 31(4):1623-8. PubMed ID: 24482188
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity and biodistribution of cisplatin nanocapsules in nude mice bearing human ovarian carcinoma xenografts.
Staffhorst RW; van der Born K; Erkelens CA; Hamelers IH; Peters GJ; Boven E; de Kroon AI
Anticancer Drugs; 2008 Aug; 19(7):721-7. PubMed ID: 18594214
[TBL] [Abstract][Full Text] [Related]
15. Use of nude mouse xenografts as preclinical drug screens: in vivo activity of established chemotherapeutic agents against melanoma and ovarian carcinoma xenografts.
Taetle R; Rosen F; Abramson I; Venditti J; Howell S
Cancer Treat Rep; 1987 Mar; 71(3):297-304. PubMed ID: 3815395
[TBL] [Abstract][Full Text] [Related]
16. Alpha-TEA plus cisplatin reduces human cisplatin-resistant ovarian cancer cell tumor burden and metastasis.
Anderson K; Lawson KA; Simmons-Menchaca M; Sun L; Sanders BG; Kline K
Exp Biol Med (Maywood); 2004 Dec; 229(11):1169-76. PubMed ID: 15564444
[TBL] [Abstract][Full Text] [Related]
17. Circumvention of cisplatin resistance in ovarian cancer by combination of cyclosporin A and low-intensity ultrasound.
Yu T; Yang Y; Zhang J; He H; Ren X
Eur J Pharm Biopharm; 2015 Apr; 91():103-10. PubMed ID: 25668779
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin-alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells.
Wang Y; Zhou J; Qiu L; Wang X; Chen L; Liu T; Di W
Biomaterials; 2014 May; 35(14):4297-309. PubMed ID: 24565522
[TBL] [Abstract][Full Text] [Related]
19. Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer.
Royer B; Delroeux D; Guardiola E; Combe M; Hoizey G; Montange D; Kantelip JP; Chauffert B; Heyd B; Pivot X
Cancer Chemother Pharmacol; 2008 Mar; 61(3):415-21. PubMed ID: 17503047
[TBL] [Abstract][Full Text] [Related]
20. Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.
Chen XX; Xie FF; Zhu XJ; Lin F; Pan SS; Gong LH; Qiu JG; Zhang WJ; Jiang QW; Mei XL; Xue YQ; Qin WM; Shi Z; Yan XJ
Oncotarget; 2015 Jun; 6(17):14926-39. PubMed ID: 25962959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
